Solid Tumor

Phase II study of 1L pembrolizumab in pts ≥ age 70 with PDL1+ NSCLC by @NadalErnest and @gecp_org now @LungCaJournal. 1Y OS rate 62% with mOS 19.2m. Confirms expectations, helpful to have prospective data. Age should not deter proper therapy. https://t.co/SqLywYzNK1 (@StephenVLiu)

Tell me about ATM alterations for the treatment of bladder cancer please. (@ClemensLaseur)

Nice shoutout to Dr @RonaYaeger trial Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer NCT05710406 public post w/ more info https://t.co/hbemZq4P6a #gdugi2023 (@fireflyann)

Researchers are studying several alterations in pancreatic cancer, among them the BRAF mutation. One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian @MPishvaian. https://t.co/jSMKge2aYR (@letswinpc)

Excited to see the latest @charlesrudin lab paper published in @ScienceTM: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity https://t.co/sKHYNaave7 (@AlvaroQuintanal)

7/7 #TumorBoardTuesday Thurs Case🎀 🙏Careful discussion & individualized care, IO can be considered in neoadj setting for pts w autoimmune dz 🤔Better biomarkers 🎯 IO in future? 📅08.08: @MMarmarelis @norataranto explore tx after progression on Osimertinib in #EGFR m #NSCLC! (@JohnEbbenMDPhD)

Analysis of CROWN data (1L lorlatinib vs crizotinib) in #ALK NSCLC by EML4-ALK fusion variant and TP53 status @JTOonline. Given the clear biologic differences between variants (v3 vs others), I think it's time to stratify by variant and tailor strategies. https://t.co/iqJzIc5KEe (@StephenVLiu)

👀 217 patients with FGFR 1-4 alteration ➡️2 median prior systemic therapies 🚨ORR: 29.5% (Prior Therapy ORR 10%) ➡️Pancreatic cancer: 55.6% ➡️Biliary Tract Cancer: 51.6% ➡️Breast Cancer: 31% …. And many more @OncoAlert @VivekSubbiah @OncBrothers @curecc (@DrShubhamPant)

Unlocking #ProstateCancer treatment: The pathway of CAR T targeting prostate stem cell antigen. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss promising options in managing advanced castration-resistant prostate cancer > https://t.co/fyZMrf16Uz (@urotoday)

For me, I have restrained giving adjuvant chemotherapy to women over 60 with resected zero or few positive node breast cancer that was heavily ER positive. I thought Tamoxifen or AI was sufficient. Pretty much every other oncologist in town gave chemotherapy. Seemed excessive. (@davideyoungmd)

We reported in 2021 p21 & Rb truncating mutations in kidney chromophobe renal cell carcinomas with suspected implications for therapy & pathogenesis. I’m fascinated by p21 & Rb truncating mutations in bladder tumors as well. More research is needed. https://t.co/RrwEr4G0Tv (@weldeiry)

Phase 3 trial results presented at the #ASCOPlenarySeries show that selinexor has the potential to extend progression-free survival in patients with wild-type TP53 advanced or recurrent #EndometrialCancer. @ASCO @OBRtweets @GynCancerMD https://t.co/Dek5NNgoxY (@AaronTallent)

Thrilled to share the stage with @LauraBukavinaMD at #BCANTT23! I'll be delving into 'PPARG the Rogue Conductor's Broken Harmony: How MAPK Pathway Alterations Drive Bladder Cancer Progression,' a new paradigm in bladder cancer. Looking forward to an exciting exchange of ideas! (@RaieBekele)

Hussein A. Tawbi, MD, PhD, and Allison Betof Warner, MD, PhD, discuss treatments for a patient with BRAF mutation–negative #melanoma. #melsm | @MDAndersonNews @StanfordCancer @DrBetofMDPhD https://t.co/iMqVhUSeET (@TargetedOnc)

Researchers are studying several alterations in pancreatic cancer, among them the BRAF mutation. One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian @MPishvaian. https://t.co/jSMKge2aYR #TumorBoardTuesday (@letswinpc)

The @lustgartenfdn recently highlighted #BCCPC collaborator @MPishvaian's work leading a study targeting a BRAF mutation in patients with #PancreaticCancer at @JohnsHopkins Great work Dr. Pishvaian! https://t.co/L9ojMLrRjh (@OHSUpancreatic)

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy. @GynCancerMD @MountSinaiMiami #gyncsm https://t.co/2uFIB9qa1N (@OncLive)

Delighted to discuss all things #BRAF on @BTOGORG podcast with @tnewsomdavis Highlighting what is known about the classes of BRAF mtn by @IbiayiMD& others, pivotal studies on BRAF/MEKi by @dplanchard @RielyMD, & use of IO @myESMO @IASLC @CancerCentreIre @IrishLungCancer #LCSM (@DrJNaidoo)

WATCH: Expert oncologists reflect on the state of molecular testing in NSCLC and how it informs the management of patients with uncommon EGFR mutations. @benlevylungdoc @hopkinskimmel @UMiamiHealth #lungcancer https://t.co/vp5pIxGdHx (@OncLive)

From science to clinical utility: @Cxbladder Detect - #BladderCancer detection for patients who present with hematuria. Tamer Aboushwareb, MD, PhD @PacificEdgeLtd, Neal Shore, MD, FACS @AtlanticUrology & @JoshMeeks @NM_Urology join to discuss on UroToday > https://t.co/ntpVmbLok6 (@urotoday)

Beyond BRCA-1 and 2: The impact of the #TALAPRO2 study on #ProstateCancer care. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber to discuss precision medicine's transformative impact on prostate cancer treatment. #WatchNow > https://t.co/1wCyan0v6L (@urotoday)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

In #clinicaltrial EA5161, investigators at are testing a new treatment approach for patients with #NSCLC w/ EGFR ex20-ins mutations. For more: https://t.co/pwy12PyvBr cc: @ZPiotrowskaMD, @LeciaSequist (@eaonc)

YUP!She updated me on a new trial for my RET mutation just before my pancreatic cancer returned. Stage 4 in liver/lungs.Been following me with regular liquid biopsies & tumor markers.Started the trial.Meds killed the cancer in 30 days!! PM me. (@randyeringler)

WATCH: @YAbdouMD, of @UNC_Lineberger, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer. #bcsm #oncology https://t.co/bm3XbNunzN (@OncLive)

Choose your player! Drs. @SusanScottMD and @Joshua_Reuss will face off at #DCLung23 on whether STK11/KEAP1 mutations should influence 1L NSCLC treatment. Visit us in downtown DC on Saturday, October 7, 2023 to vote! Full agenda registration at: https://t.co/rJa81GX23a (@StephenVLiu)

Delighted to share our latest paper on the mechanistic modeling of disease progression in EGFR-mutant lung adenocarcinoma: https://t.co/dsB0zfo9rc A special thanks to @MDuruisseaux & to all co-authors from @novadiscovery , @JanssenFRA. (@Claudio_MonT_s)

Things may be looking up in #coloncancer care as data from ongoing trials is uncovered. Explore metastatic #colorectalcfancer further with Dr. Charles Turck as he speaks with @MoffittNews’ Dr. Richard Kim and @benweinbergmd from @MedStarHealth: https://t.co/XtIKiAH16R (@ReachMD)

@ALKLungCancer @EGFRResisters @lcfamerica @KRASKickers @brownbeansprout @jillfeldman4 @bjork5 @AboutLungCancer @LungCancerFaces @chrisdraft @ivybelkin @LungCancerRx @LungCancerEu @IASLC @LUNGFORCE @lcrf_org @LungAssociation @ALKPositiveinc (@RManochakian)

Join us for this fun + inspiring “thinktank” to study #EGFR-mutant #lungcancer with a great community! Meet the incredible @jillfeldman4 + @ivybelkins! Link for abstract submission below. Deadline 8/18. #hemeoncfellows @OncoAlert #LCSM @EGFRResisters @EGFRSummit https://t.co/SiobKVyQKA (@christine_lovly)

A recent study published in JNCI Cancer Spectrum demonstrates the real-world utility of @Veracyte's #Decipher Prostate Genomic Classifier in #ProstateCancer treatment. #ReadNow details on UroToday > https://t.co/NOVWZFh6wC @JNCI_Now @DrSpratticus @Davicioni (@urotoday)

1. Lessons from Melanoma: Building on PD1 backbone w/ CTLA/LAG3 (FS Hodi, @wolchokj, @MPostow) 2. What’s new in IrAE mgmt? @DrJNaidoo @CardioOncology @kreynoldsMD 3. RCC Germline Genetics: Past, Present, Future (Linehan,@KidneyCancerDoc @pearldaily) 4. @kidneycan FallAdvocacy (@MikeSerzanMD)

JUST IN: @FDAOncology approved dostarlimab (PD-1 inh, GSK) w/carboplatin+paclitaxel, followed by single-agent dostarlimab, for dMMR/MSI-H metastatic endometrial cancer. Approval based on RUBY trial published in @NEJM 2023 https://t.co/QAkLNAnmWy @OncoAlert @OncBrothers (@DrChoueiri)

⁦@US_FDA⁩ ‘s Withdrawal of Later-Line Indication For #Olaparib in #BRCA Mutated #OvarianCancer ⁦@OncLive⁩ #gyncsm #womenshealth #cancerresearch #PARP https://t.co/MY9RghtCLp (@LguzzardiM)

Delighted to share our latest paper on “Tumor-agnostic drug development in dMMR/MSI-H solid tumors” just published in Trends in Cancer – @VivekSubbiah #cancer #immunotherapy #drugs #research #precisionmedicine #tumor #oncology #oncodaily https://t.co/u1dVByzRJM (@oncodaily)

WATCH: Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer @MirzaCPH @Rigshospitalet @US_FDA #gyncsm https://t.co/znzrC40eHt (@OncLive)

PSMA-targeted radioligand therapy and #LiquidBiopsy characterizing #PSMA expression in men with metastatic castration-resistant #ProstateCancer. @AarmstrongDuke @DukeCancer joins @AndreaMiyahira @PCFnews to discuss the #PROPHECY trial on UroToday > https://t.co/tTiFnUVJOv (@urotoday)

The GLOW study is published! Kudos to the GI Oncology community and our patients. Zolbetuximab should be considered a standard option for CLDN18.2 positive gastroesophageal adenocarcinoma! @drallysonocean @pashtoonkasi @nyphospital @WCM_MeyerCancer https://t.co/G0wWPLz2Zr (@mdmanishshah)

FDA Approves Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer https://t.co/cJNILT0V1t via @targetedonc #MedTwitter #OncTwitter #ecsm (@dawood_findakly)

In the phase 3 GLOW trial, CAPOX plus zolbetuximab significantly improved progression free survival and overall survival in patients with CLDN18.2+, HER2- untreated #GastricCancer or gastroesophageal junction adenocarcinoma @AstellasUS @mdmanishshah https://t.co/YYbLHhiyOq (@NatureMedicine)

Folate receptor alpha widely expressed and potential therapeutic target in uterine and ovarian carcinosarcoma @ISGynP @SGO_org @IGCSociety @ESGO_society @ASCO @OncoAlert https://t.co/v51f4ROiIw (@gynoncjnls)

@ClaudioVladmir comenta estudo publicado online no Lung Cancer Journal que mostrou que a superexpressão de VEGFR2 foi independentemente associada com maior SG e maior SLP em pacientes com mesotelioma pleural - https://t.co/rulqlKcp5f @acccancercenter #MESOTELIOMA #ONCONEWS (@PortalOnconews)